Telehealth Semaglutide and Lawsuit Eligibility: The Novo Nordisk-Hims Deal Explained

The telehealth GLP-1 market has exploded since 2022, with companies like Hims & Hers, Amazon Pharmacy, and others offering prescription semaglutide through online consultations. Many of these prescriptions are for compounded versions of semaglutide—custom-made formulations produced by pharmacy compounders rather than manufactured by Novo Nordisk (the maker of brand-name Ozempic and Wegovy).

Now, a new partnership between Novo Nordisk and Hims & Hers is raising important questions: How will this deal change the landscape of GLP-1 prescribing? And most importantly for injured patients—could it affect your eligibility for the ongoing Ozempic/Wegovy lawsuit?

Understanding Compounded Semaglutide

Compounded semaglutide is not brand-name Ozempic or Wegovy. Instead, it’s a custom-made version prepared by licensed pharmacy compounders using raw semaglutide powder. Compounders mix, package, and distribute these formulations directly to patients, often at lower costs and with faster shipping than traditional pharmacies.

The FDA has raised concerns about compounded semaglutide in the past—particularly regarding quality control, sterility, and consistency. Unlike FDA-approved brand-name products, compounded drugs receive less regulatory oversight before reaching patients. This doesn’t automatically mean they’re unsafe, but it does mean patients may face additional risks if manufacturing standards vary.

The Novo Nordisk-Hims & Hers Partnership

In 2026, Novo Nordisk announced a partnership framework with Hims & Hers to distribute prescription GLP-1 medications through the telehealth platform. While the full terms remain confidential, early reports suggest:

• Hims & Hers may transition from compounded semaglutide to brand-name Novo Nordisk formulations (Ozempic or Wegovy)
• Pricing and availability terms are still under negotiation
• The deal could reshape how telehealth companies source and distribute GLP-1 drugs

This represents a significant market shift for telehealth, which has largely relied on compounded alternatives to meet demand and manage costs.

Legal Implications for Injured Patients

If you’ve been injured by semaglutide and are considering joining the GLP-1 injury lawsuit, here are the key legal questions:

Does the drug source matter?

The GLP-1 injury MDL generally focuses on brand-name products—Ozempic (prescribed for diabetes) and Wegovy (prescribed for weight loss). The complaint specifically names these FDA-approved formulations. Compounded semaglutide occupies a legal gray zone: while it’s the same active ingredient, it lacks the regulatory history and labeling of brand-name drugs.

Courts may view compounded semaglutide differently because compounding involves different manufacturing standards, different inactive ingredients, different warning labels, and different liability pathways. Learn more about how multidistrict litigation works through the federal Judicial Panel on Multidistrict Litigation (JPML).

Will this deal clarify eligibility?

If Hims & Hers transitions to brand-name products, future patients will have clearer liability chains. But what about patients who already took compounded semaglutide? That remains legally ambiguous—and is exactly why acting now matters.

GLP-1 Safety and Compounded Medications

According to the NIH National Institute of Diabetes and Digestive and Kidney Diseases, GLP-1 medications carry documented risks including pancreatitis, gastroparesis, and gallbladder disease. Medical literature on GLP-1 adverse events continues to emerge as more patients use these drugs.

Compounded versions may lack the same pre-market testing and post-market surveillance as brand-name drugs. The FDA distinguishes between licensed compounders (which follow pharmaceutical standards) and unlicensed operations. Determining whether your prescription came from a properly licensed, regulated compounder is critical for establishing liability.

Questions Telehealth Patients Should Ask

If you purchased semaglutide through Hims & Hers, Amazon Pharmacy, Ro, GoodRx, or another telehealth service, investigate your medication history:

• Brand-name or compounded? Check receipts and pharmacy paperwork. Brand-name products clearly label “Ozempic” or “Wegovy.”
• Timing of use? Statute-of-limitations deadlines apply.
• Injuries experienced? The lawsuit covers gastroparesis, bowel obstruction, pancreatitis, and gallbladder disease—among others.

Why the Timing Matters

The regulatory and legal landscape for compounded GLP-1 medications is still evolving. The Novo Nordisk-Hims deal may accelerate industry-wide transition toward brand-name products, potentially phasing out compounding operations. For injured patients, this creates an urgent window to act.

Once the telehealth market fully shifts and the distinction becomes entrenched, courts may become less flexible about accepting compounded semaglutide cases into the MDL. Early action strengthens your legal foundation and protects you from statute-of-limitations deadlines.

Take the Next Step

If you’ve experienced serious injuries after using semaglutide—whether brand-name or compounded—don’t wait to explore your legal options. Our firm specializes in GLP-1 injury litigation and understands how medication sourcing affects your case.

Get your free case review today—we’ll assess your claim at no cost and with no obligation.